Remedor Biomedis a wound healing clinical research stage biopharmaceutical company that develops medications for skin wounds that do not respond well to current treatment options. The company's technology platform is based on a formulation containing a naturally occurring glycoprotein, erythropoietin, which is active in each phase of the healing process.
The company focuses on complex wounds such as diabetic foot ulcer and deep burn wounds. Its cutting-edge innovation is a unique proprietary topical biologic technology platform based on a smart hydrogel-matrix that withstands extreme temperature fluctuations and delivers the active substance on the wound bed effectively.